Bruker (BRKR) 2024 Wells Fargo Healthcare Conference summary

Management strategy and operational execution

• Bruker management process, established in 2014, has driven reliable execution and margin expansion, blending operational rigor with entrepreneurial flexibility.

• Case studies include transforming Siemens AXS from a $50M loss-maker to a $300M market leader and Jordan Valley Semiconductors from $20M to $100M with significant margin improvements.

• Recent ELITechGroup acquisition created a $500M business with over 60% gross margin and 30%+ operating margin, integrating into the management process for further gains.

• Over eight years, achieved 1,000 basis points of margin expansion, with strategic acquisitions expected to become high-margin market leaders.

Market outlook and growth drivers

• Organic growth outperformed the sector from 2021–2023, but double-digit growth is not expected in 2024–2025; still projecting 500–600 basis points above market.

• Portfolio transformation through Project Accelerate and expansion into post-genomic fields like proteomics, spatial biology, and automation positions the company for long-term growth.

• Secular trends in non-genomic applications, such as proteomics and spatial biology, are stronger than traditional markets, supporting continued outperformance.

End market and geographic performance

• Biopharma, about 15% of revenue, is currently muted due to price controls and cautious spending, with a turnaround expected in 2025.

• Academic and government segments are healthy, driven by medical research centers and philanthropic funding, especially in proteomics and spatial biology.

• China represents 15% of revenue; stimulus-driven demand is high, but order flow is expected to materialize mainly in 2025–2026 due to decentralized provincial administration.